首页> 美国卫生研究院文献>other >Rod Photoreceptor Temporal Properties in Retinitis Pigmentosa
【2h】

Rod Photoreceptor Temporal Properties in Retinitis Pigmentosa

机译:杆光感受器在视网膜炎中的颞性能

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

One of the characteristic signs of retinitis pigmentosa (RP) is the progressive loss of night vision. We have previously shown that the gain of rod photoreceptor activation is moderately reduced in some patients with RP, but this decrease in activation kinetics is not sufficient to account for the night blindness. Recently, single rod recording from animal models of RP showed rods under degeneration remain saturated for shorter periods than normal rods; i.e. are less able to sustain the rod photoresponse. Using paired-flash ERG, here we determine whether rod phototransduction inactivation parameters might also be abnormal in patients with RP. Inactivation parameters were derived from 13 subjects with normal vision, 16 patients with adRP, and 16 patients with autosomal recessive/isolate (rec/iso) RP. The adRP cases included 9 patients with rhodopsin mutations and 7 patients with peripherin/RDS mutations. The inactivation phase was derived using a double-flash paradigm, with a test flash of 2.7 log scot td-sec followed at varying intervals by a 4.2 log scot td-sec probe flash. Derived rod photoresponses to this just-saturating test flash in normal subjects exhibit a critical time to the initiation of recovery (Tsat) of 525±90 (SD) msec. The values of Tsat were 336±104 (SD) msec in patients with adRP (P<0.001) and 271±45 (SD) msec (P<0.001) in patients with rec/iso RP. When Tsat values were categorized by mutations, the values were 294±91 (SD) msec (P<0.001) for rhodopsin mutations, and 389±100 (SD) msec (p=0.01) for peripherin/RDS mutations. Overall, Tsat in patients with RP was significantly correlated with the amplitude of ISCEV standard rod response (r = 0.56; P < 0.001) and the gain of the activation phase of phototransduction (r=0.6, P<0.001). Tsat may be a useful marker for therapeutic efficacy in future clinical trials in RP.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号